AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The British health agency had previously advised under-30s to seek a different vaccine.

Here's Why The U.K. Is Offering Under-40s Alternatives To The AstraZeneca Covid-19 Vaccine

A very small number of people who have been inoculated with the AstraZeneca vaccine have suffered blood clots.

UK to offer under-40s alternative to AstraZeneca Covid-19 vaccine given rare blood clot concerns

The UK is offering everyone under 40 an alternative to the AstraZeneca COVID-19 vaccine, citing concerns over the development of blood clots among vaccinated young people. The new advisory from the UK's Joint Committee on Vaccination and Immunisation published Friday.

The UK is offering people under 40 an alternative to AstraZeneca's COVID-19 vaccine following concerns about blood clots in young people

People under the age of 40 in the U.K. will be offered an alternative to the AstraZeneca COVID-19 vaccine as a precautionary measure, following concerns of rare blood clots linked to the shot, several news media outlets reported on Thursday.

Under-40s to be offered alternative COVID-19 vaccines to AstraZeneca in U.K.: reports

AstraZeneca PLC (LON:AZN) has shared positive results from a final-stage trial on its drug Imfinzi for non-small cell lung cancer (NSCLC) patients. The candidate was analysed in combination with platinum-based chemotherapy, or antibody tremelimumab and chemotherapy, compared to chemotherapy alone, as primary treatment for patients at stage IV of cancer.

AstraZeneca posts positive final-stage trial results for lung cancer treatment

BioNTech SE

Johnson & Johnson

Moderna

Novavax

Pfizer

Pfizer fell Thursday by as much as 5% from Wednesday's close while Moderna dipped by almost 12% before both stocks recovered most of those losses.

Covid vaccine makers' shares seesaw after Biden administration says it will back patent waivers

Several countries have stopped using the shot over fears of blood clots despite numerous regulators asserting the benefits of the vaccine outweighs the risks.

New Study Finds ‘Small' Blood Clot Risk After One AstraZeneca Vaccine Dose, Rates Are Higher Than Expected For General Population

The EU doesn't think the big drugmaker has held up its end of a supply agreement.

Why is the EU Suing AstraZeneca?

If enacted, such a move would hit the smaller vaccine makers particularly hard.

Biden Administration Supports Patent Waivers for Coronavirus Vaccine

According to real-world data released by South Korea, one dose of COVID-19 vaccines from AstraZeneca Plc (NASDAQ: AZN) and Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) was 86.6% effective in preventing infections among people aged 60 and older, reports Reuters. Data revealed by the Korea Disease Control and Prevention Agency (KDCA) showed the Pfizer/BioNTech shot was 89.7% effective in preventing infection at least two weeks after a first dose was given.

Single Shot Of AstraZeneca, Pfizer COVID-19 Vaccines Provide 87% Protection, South Korea Study Shows: Reuters

The Pfizer shot was 89.7% effective, and AstraZeneca was 86% effective in preventing infections among people over-60 after a single dose, according to South Korean officials.

AstraZeneca And Pfizer Covid-19 Vaccines More Than 86% Effective After First Dose, South Korean Authorities Say

CAMBRIDGE, England--(BUSINESS WIRE)--Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, has formed a collaboration with AstraZeneca to accelerate prostate cancer research. Alchemab and AstraZeneca (LSE/STO/Nasdaq: AZN) will work together on a proof-of-concept study to build understanding of the fundamental biology of prostate cancer. Under the agreement, Alchemab's novel drug discovery pl

Alchemab to Collaborate With AstraZeneca to Use Alchemab's Drug Discovery Platform for Prostate Cancer Study

Benzinga's Stock Wars series matches up two leaders in a major industry sector, with the goal of letting readers decide which company is the better investment. In this week's installment, we take a look at two pharmaceutical giants at the forefront of the COVID-19 vaccine development: AstraZeneca plc (NASDAQ:AZN) and Pfizer Inc. (NYSE:PFE).

Stock Wars: AstraZeneca Vs. Pfizer

Advisory groups ask shareholders to oppose bid to raise Pascal Soriot's maximum share bonus to 650% of £1.3m basic pay

‘Obscene' bonus hike for AstraZeneca boss prompts investor anger

AstraZeneca PLC's (LON:AZN) shares have decoupled from the vaccine headlines, Barclays commented. The stock has jumped 4% since Friday, when it posted a quarterly update including a bullish statement on its outlook.

AstraZeneca shares have decoupled from vaccine headlines, says Barclays

AstraZeneca PLC (LON:AZN) announced that Farxiga has been approved in the US by the Food and Drug Administration (FDA). It will be given to adults with chronic kidney disease (CKD) at risk of progression to reduce the risk of decline of the condition to the stage where kidneys can't function on their own, cardiovascular death and hospitalisation for heart failure.

AstraZeneca receives US approval for chronic kidney disease drug

3 Big Drugmaker Stocks to Watch Out For Amid Pandemic Woes

The FDA has approved AstraZeneca plc's (NASDAQ: AZN) Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 inhibitor, to treat chronic kidney disease (CKD) even in patients without diabetes. Under the new approval, Farxiga can be used to reduce the risk of declining kidney function, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with CKD.

AstraZeneca's Diabetes Drug Farxiga Scores FDA Nod In Kidney Disease

AstraZeneca PLC's (AZN) CEO Pascal Soriot on Q1 2021 Results - Earnings Call Transcript

AstraZeneca PLC (NASDAQ: AZN) shares are trading higher after the company reported better-than-expected EPS and sales results. AstraZeneca reported first-quarter adjusted earnings per share of $0.82, which beat analyst estimates of $0.75.

Why Is AstraZeneca's Stock Trading Higher Today?

AstraZeneca (AZN) surpasses first-quarter estimates on both counts. Stock up in pre-market.

AstraZeneca (AZN) Q1 Earnings Top, COVID-19 Vaccine Adds $275M

The company reported better-than-expected first-quarter results.

Why AstraZeneca Stock Is Jumping Today

AstraZeneca stock jumped 3.4% in early trading on Friday, as the U.K.-Swedish drug company reported better-than-expected earnings, led by its blockbuster cancer drugs.

AstraZeneca reveals COVID-19 vaccine sales but that isn't why the stock is rising

Pascal Soriot says firm is doing its best to produce more and ‘should be proud of what we did in the world'

AstraZeneca CEO hits back at Covid vaccine supply criticism

AstraZeneca Plc (NASDAQ: AZN) generated $275 million in revenue from its non-profit COVID-19 vaccine in Q1. Still, it has not been able to keep up with its costs, resulting in a hit to core earnings by $0.03 and a warning the vaccine effort could continue to affect margins.

News for AstraZeneca Stock (AZN)